Evaluation of isradipine (PN 200-110) in mild to moderate hypertension

Nathaniel Winer, Susan Thys-Jacobs, Raminder Kumar, Warren D. Davidson, Martha Grayson, Calvin Harris, Deborah Walker, Harold Itskovitz, Leonard Gonasun

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The efficacy and safety of isradipine (PN 200-110), a new dihydropyridine calcium antagonist, was evaluated in 87 hypertensive patients in a placebo-controlled, double-blind, randomized multicenter trial. After a 3-week single-blind washout phase, isradipine (or matching placebo) was administered for 4 weeks, beginning at 2.5 mg b.i.d. with increments of 2.5 mg b.i.d. at weekly intervals if supine diastolic blood pressure remained ≥90 mm Hg. At the end of 1 week average supine blood pressure in the isradipine group (n = 45) fell from a baseline of 156 ± 13 104 ± 4 mm Hg to 146 ± 14 97 ± 7 mm Hg. By week 4 blood pressure was reduced by 19 14mm Hg compared with 4 5mm Hg in the placebo group (P < 0.001 between groups). Supine and standing pulse rates were slightly increased initially with isradipine therapy but returned to baseline with increasing isradipine doses. Blood pressure responses at week 4 were good or excellent (supine diastolic ≤90 mm Hg or ≥10 mm Hg decrease from baseline) in 87% of isradipine-treated patients and in 26% of placebo-treated patients. Headache, edema, abdominal discomfort, and constipation occurred slightly more frequently in isradipine-treated patients than in placebo-treated control subjects. The results indicate that isradipine, administered as monotherapy in doses of 2.5 to 10 mg b.i.d., is safe and effective in patients with mild to moderate essential hypertension.

Original languageEnglish (US)
Pages (from-to)442-448
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume42
Issue number4
StatePublished - Oct 1987
Externally publishedYes

Fingerprint

Isradipine
Hypertension
Placebos
Blood Pressure
Constipation
Multicenter Studies
Headache
Edema
Heart Rate
Calcium
Safety

ASJC Scopus subject areas

  • Pharmacology

Cite this

Winer, N., Thys-Jacobs, S., Kumar, R., Davidson, W. D., Grayson, M., Harris, C., ... Gonasun, L. (1987). Evaluation of isradipine (PN 200-110) in mild to moderate hypertension. Clinical Pharmacology and Therapeutics, 42(4), 442-448.

Evaluation of isradipine (PN 200-110) in mild to moderate hypertension. / Winer, Nathaniel; Thys-Jacobs, Susan; Kumar, Raminder; Davidson, Warren D.; Grayson, Martha; Harris, Calvin; Walker, Deborah; Itskovitz, Harold; Gonasun, Leonard.

In: Clinical Pharmacology and Therapeutics, Vol. 42, No. 4, 10.1987, p. 442-448.

Research output: Contribution to journalArticle

Winer, N, Thys-Jacobs, S, Kumar, R, Davidson, WD, Grayson, M, Harris, C, Walker, D, Itskovitz, H & Gonasun, L 1987, 'Evaluation of isradipine (PN 200-110) in mild to moderate hypertension', Clinical Pharmacology and Therapeutics, vol. 42, no. 4, pp. 442-448.
Winer N, Thys-Jacobs S, Kumar R, Davidson WD, Grayson M, Harris C et al. Evaluation of isradipine (PN 200-110) in mild to moderate hypertension. Clinical Pharmacology and Therapeutics. 1987 Oct;42(4):442-448.
Winer, Nathaniel ; Thys-Jacobs, Susan ; Kumar, Raminder ; Davidson, Warren D. ; Grayson, Martha ; Harris, Calvin ; Walker, Deborah ; Itskovitz, Harold ; Gonasun, Leonard. / Evaluation of isradipine (PN 200-110) in mild to moderate hypertension. In: Clinical Pharmacology and Therapeutics. 1987 ; Vol. 42, No. 4. pp. 442-448.
@article{257fc7cc221746b6943240c574b5bce0,
title = "Evaluation of isradipine (PN 200-110) in mild to moderate hypertension",
abstract = "The efficacy and safety of isradipine (PN 200-110), a new dihydropyridine calcium antagonist, was evaluated in 87 hypertensive patients in a placebo-controlled, double-blind, randomized multicenter trial. After a 3-week single-blind washout phase, isradipine (or matching placebo) was administered for 4 weeks, beginning at 2.5 mg b.i.d. with increments of 2.5 mg b.i.d. at weekly intervals if supine diastolic blood pressure remained ≥90 mm Hg. At the end of 1 week average supine blood pressure in the isradipine group (n = 45) fell from a baseline of 156 ± 13 104 ± 4 mm Hg to 146 ± 14 97 ± 7 mm Hg. By week 4 blood pressure was reduced by 19 14mm Hg compared with 4 5mm Hg in the placebo group (P < 0.001 between groups). Supine and standing pulse rates were slightly increased initially with isradipine therapy but returned to baseline with increasing isradipine doses. Blood pressure responses at week 4 were good or excellent (supine diastolic ≤90 mm Hg or ≥10 mm Hg decrease from baseline) in 87{\%} of isradipine-treated patients and in 26{\%} of placebo-treated patients. Headache, edema, abdominal discomfort, and constipation occurred slightly more frequently in isradipine-treated patients than in placebo-treated control subjects. The results indicate that isradipine, administered as monotherapy in doses of 2.5 to 10 mg b.i.d., is safe and effective in patients with mild to moderate essential hypertension.",
author = "Nathaniel Winer and Susan Thys-Jacobs and Raminder Kumar and Davidson, {Warren D.} and Martha Grayson and Calvin Harris and Deborah Walker and Harold Itskovitz and Leonard Gonasun",
year = "1987",
month = "10",
language = "English (US)",
volume = "42",
pages = "442--448",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Evaluation of isradipine (PN 200-110) in mild to moderate hypertension

AU - Winer, Nathaniel

AU - Thys-Jacobs, Susan

AU - Kumar, Raminder

AU - Davidson, Warren D.

AU - Grayson, Martha

AU - Harris, Calvin

AU - Walker, Deborah

AU - Itskovitz, Harold

AU - Gonasun, Leonard

PY - 1987/10

Y1 - 1987/10

N2 - The efficacy and safety of isradipine (PN 200-110), a new dihydropyridine calcium antagonist, was evaluated in 87 hypertensive patients in a placebo-controlled, double-blind, randomized multicenter trial. After a 3-week single-blind washout phase, isradipine (or matching placebo) was administered for 4 weeks, beginning at 2.5 mg b.i.d. with increments of 2.5 mg b.i.d. at weekly intervals if supine diastolic blood pressure remained ≥90 mm Hg. At the end of 1 week average supine blood pressure in the isradipine group (n = 45) fell from a baseline of 156 ± 13 104 ± 4 mm Hg to 146 ± 14 97 ± 7 mm Hg. By week 4 blood pressure was reduced by 19 14mm Hg compared with 4 5mm Hg in the placebo group (P < 0.001 between groups). Supine and standing pulse rates were slightly increased initially with isradipine therapy but returned to baseline with increasing isradipine doses. Blood pressure responses at week 4 were good or excellent (supine diastolic ≤90 mm Hg or ≥10 mm Hg decrease from baseline) in 87% of isradipine-treated patients and in 26% of placebo-treated patients. Headache, edema, abdominal discomfort, and constipation occurred slightly more frequently in isradipine-treated patients than in placebo-treated control subjects. The results indicate that isradipine, administered as monotherapy in doses of 2.5 to 10 mg b.i.d., is safe and effective in patients with mild to moderate essential hypertension.

AB - The efficacy and safety of isradipine (PN 200-110), a new dihydropyridine calcium antagonist, was evaluated in 87 hypertensive patients in a placebo-controlled, double-blind, randomized multicenter trial. After a 3-week single-blind washout phase, isradipine (or matching placebo) was administered for 4 weeks, beginning at 2.5 mg b.i.d. with increments of 2.5 mg b.i.d. at weekly intervals if supine diastolic blood pressure remained ≥90 mm Hg. At the end of 1 week average supine blood pressure in the isradipine group (n = 45) fell from a baseline of 156 ± 13 104 ± 4 mm Hg to 146 ± 14 97 ± 7 mm Hg. By week 4 blood pressure was reduced by 19 14mm Hg compared with 4 5mm Hg in the placebo group (P < 0.001 between groups). Supine and standing pulse rates were slightly increased initially with isradipine therapy but returned to baseline with increasing isradipine doses. Blood pressure responses at week 4 were good or excellent (supine diastolic ≤90 mm Hg or ≥10 mm Hg decrease from baseline) in 87% of isradipine-treated patients and in 26% of placebo-treated patients. Headache, edema, abdominal discomfort, and constipation occurred slightly more frequently in isradipine-treated patients than in placebo-treated control subjects. The results indicate that isradipine, administered as monotherapy in doses of 2.5 to 10 mg b.i.d., is safe and effective in patients with mild to moderate essential hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0023633115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023633115&partnerID=8YFLogxK

M3 - Article

C2 - 2959426

AN - SCOPUS:0023633115

VL - 42

SP - 442

EP - 448

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -